STAT

Opinion: Diversity in clinical trials defines good science and better medicine

Diversity in clinical trials remains low despite a 25-year-old law that requires all federally funded clinical research to prioritize including underserved racial and ethnic groups.

Hispanic Americans have higher levels of diabetes and less access to health care services, yet they live on average about three years longer than non-Hispanic whites and six years longer than African-Americans.

Why?

No one really knows. Hispanics are underrepresented in both clinical trials and the genome-wide association studies that have informed our understanding of the molecular foundation of health and disease, so we can only guess.

But new research is offering some insights. A study suggests that people age differently based

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks